Please ensure Javascript is enabled for purposes of website accessibility

Instant Analysis: Gilead Sciences Raises Its Dividend 10%

By Brian Feroldi – Feb 3, 2016 at 2:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Putting more cash directly into shareholders' pockets.

What's happening?
Biotech bluechip Gilead Sciences (GILD -2.19%) announced today that it will be raising its dividend payment by 10% starting in the second quarter of 2016. Its new payout will be $0.47 per share per quarter, which gives its shares a forward yield of roughly 2.2% at current market prices.

In addition, Gilead's Board of Directors approved an additional $12 billion share repurchase program that will kick in once the company's current $15 billion repurchase program is completed. As of the end of 2015 Gilead had approximately $8 billion remaining under its old plan, but that number should dwindle quickly as the company plans repurchase $5 billion worth of shares in first quarter of 2016. 

Does it matter?
In the release, Gilead's outgoing CEO John Martin stated:

Today's announcement reflects confidence in the company's long term cash flows and our commitment to use our cash to invest for future growth and deliver shareholder return.

With the company's stock down roughly 30% from its summer time highs, I think it's a great time for the company to get aggressive with its efforts to return capital to shareholders. The market appears to agree as shares are up roughly 3% today.

Still, it's not all sunshine and roses for Gilead. It will be an uphill battle in 2016 as Gilead's hepatitis C drugs Harvoni and Sovaldi will face new competition now that Merck's drug Zepatier has won FDA approval. That's especially true when considering that Merck plans to win market share by competing heavily on price. Zepatier costs $54,600, a 42% discount to the list price of Gilead's Harvoni.

Only time will tell what kind of impact Merck's aggressive pricing strategy will have on Gilead's financial statements, but as long as Gilead share price continues to sag I applaud management's move to return more cash to shareholders. 

Brian Feroldi owns shares of Gilead Sciences. The Motley Fool owns shares of and recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
$61.69 (-2.19%) $-1.38

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.